On November 18, 2024, the Food and Drug Administration (FDA) carried out an inspection at Sightlife in Seattle, concentrating on human cellular, tissue, and gene therapies, according to data posted on the FDA’s website.
According to the final report, Sightlife was not required to make any corrective actions regarding its operational management.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
